NCT07693751 SOT-109 Advanced Colorectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07693751 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07693751 is a hot trial to watch
Advanced Colorectal Adenocarcinoma is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07693751 is notable because it evaluates SOT-109 in a Phase 1/2 design sponsored by SOTIO Biotech as. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07693751 |
| Official title | A Study Testing SOT109 for the First Time in Patients, to Assess How Safe SOT109 is, How Well it Works, and How the Body Handles it in Patients With Advanced Colorectal Cancer That Can Not be Removed by Surgery or is Metastatic |
| Phase / status | Phase 1/2 / Not yet recruiting |
| Intervention | SOT-109 |
| Sponsor | SOTIO Biotech as |
| Geography | United States, Moldova |
| Enrollment | [object Object] |
| Primary endpoint | Part A: Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SOT109 |
| Endpoint time frame | At the end of Cycle 1 (one cycle is 21 days) |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
SOT109 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called CDH17, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B. The goal of Part A is to collect information about SOT109, understand its effects, and see whether it is safe and well tolerated at different dose levels. Part B of the study collects information on which of the two selected safe dose levels chosen in Part A gives the best balance between benefit and risk.
Allocation is Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment. Planned enrollment of [object Object] participants across United States, Moldova shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Part A: Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SOT109 (At the end of Cycle 1 (one cycle is 21 days)) — MTD will be selected as guided by the time to-event Bayesian optimal interval (TITEBOIN) design. The RP2D will be selected based on integrated evaluation of the totality of clinical and preclinical data, for all dose levels tested.
- Part B: Optimal dose of SOT109 for subsequent clinical trials (Cycle 1 Day 1 up to 30 days after the last dose (each cycle is 21 days)) — Assessment of the safety and tolerability of two recommended doses under evaluation for dose optimization (RDOs) of SOT109 by evaluation of the occurrence of SOT109 related TEAEs, serious TEAEs, TEAEs leading to premature discontinuation of SOT109, deaths, and clinical laboratory test abnormalities of grade 3 or higher according to NCI CTCAE Version 6.0
- Part B: Objective Response Rate (ORR) of SOT109 (From Day 1 of Cycle 1 (one cycle is 21 days) until disease progression, initiation of new anticancer therapy, withdrawal of consent, or study discontinuation, whichever comes first, to be assessed up to approximately 9 months) — Percentage of participants who achieve a Best Overall Response of Complete Response (CR) or Partial Response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Part B: Duration of Response (DoR) of SOT109 (From the date of first documented objective response until disease progression, initiation of new anticancer therapy, withdrawal of consent, or study discontinuation, whichever comes first, assessed up to approximately 9 months.) — The time from the first documentation of objective response (CR or PR) to the first documented date of progressive disease (PD) according to RECIST v1.1.
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: SOT-109 is indexed as Antibody drug conjugate (ADC), with target CDH17 x Top I, mechanism CDH17 antagonists, TOP1 inhibitors, and global highest development status Phase 1/2.
Company & Deal Intelligence MCP profile: SOTIO Biotech as is resolved to a normalized organization record in Czechia. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07693751 provides a focused lens on Advanced Colorectal Adenocarcinoma development. Its value will be determined by whether SOT-109 can convert the current Phase 1/2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
